HealthQuad, a healthcare-focused venture capital firm backed by Quadria Group, has announced the first close of its third fund with commitments of ₹550 crore, approximately $58.2 million. This initial closing represents over a third of the fund's total target of ₹1,700 crore, or about $180 million. The new fund will continue to support early-growth stage companies revolutionizing India's healthtech landscape.
Strategic Investment Focus
Fund III is set to invest in 13 to 15 innovative startups across key sectors including AI-driven healthcare, digital therapeutics, and enterprise SaaS. The investment strategy is predominantly focused on the burgeoning Indian market. A discretionary portion of the capital is also allocated for strategic opportunities in other Southeast Asian markets.
The fund has already made its inaugural investment in LifeSigns, an advanced AI-powered platform for remote patient monitoring. This initial transaction underscores the fund's proactive approach to building its portfolio with promising ventures. HealthQuad is actively evaluating other proprietary deals to establish early visibility and momentum for its new fund.
Evolved Corporate Structure
The new fund is managed by HealthQuad Advisors, a vehicle wholly owned by Quadria Group through its partners Amit Varma, Abrar Mir, and Sunil Thakur. This structure follows the 2025 mutual separation between Quadria and its former partner, Belgium-based impact investor KIOS. Quadria Group has now assumed full control of the HealthQuad platform, aligning it more closely with its broader healthcare investment strategy.
To ensure continuity, the firm has retained the majority of the team that managed its first two successful funds. The leadership has been further strengthened with the addition of partners Rahul Agarwal and Namit Chugh. This experienced team will leverage Quadria's extensive network to support portfolio companies across India and Southeast Asia.
Market Opportunity and Investment Philosophy
HealthQuad's latest fund is timed to capitalize on the rapid technology adoption within India's healthcare industry. The firm aims to back new-age models that supplement and enhance existing healthcare infrastructure, addressing critical gaps in the system. Projections indicate that tech-enabled solutions could account for nearly 40% of India's total healthcare spending by 2030.
The firm distinguishes itself with a rigorous, private equity-style diligence process, often tracking potential investments for several years. It specifically targets companies developing "clinical grade AI" that has received regulatory validation from authorities in India, the US, or Europe. This disciplined approach ensures investments are made in sustainable, market-leading companies with long-term clinical relevance.
The fund's target corpus of ₹1,700 crore is complemented by a greenshoe option that could increase its total size to ₹2,500 crore. The first close saw participation from both existing and new limited partners, including global institutions, fund-of-funds, and family offices. HealthQuad expects to achieve the final close of the fund by the middle of the upcoming year.
The successful first close of Fund III highlights significant investor confidence in HealthQuad's specialized focus and the vast potential of India's healthtech sector. Backed by the extensive resources of Quadria Group, the fund is strategically positioned to drive innovation and cultivate the next generation of healthcare leaders. This new capital will play a crucial role in shaping a more technologically advanced and accessible healthcare ecosystem in the region.